13 terminated. 13 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b - Melanoma, Cancer | Phase 2 | Terminated | Sanofi Pasteur, a Sanofi Company | 23 | 2008-06-01 | 2016-04-14 |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma Decitabine, Interferon Alfa-2b - Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2007-10-01 | 2011-12-26 |
| Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines Interferon Alfa-2a - Cancer | Phase 2 | Terminated | Duke University | 11 | 2005-11-01 | 2014-07-25 |
| Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer PEG-interferon alfa-2a, Capecitabine - Breast Cancer, Metastatic Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2005-09-01 | 2012-12-11 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis - Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 40 | 2004-10-01 | 2013-07-02 |
| Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma recombinant interferon alfa, thalidomide, laboratory biomarker analysis - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2001-07-01 | 2013-01-25 |
| Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer recombinant interferon alpha-2b, isotretinoin, paclitaxel - Cervical Cancer | Phase 2 | Terminated | University of Medicine and Dentistry of New Jersey | 33 | 2001-03-01 | 2013-11-20 |
| Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Pegylated interferon alfa-2b, Interferon alfa-2b - Chronic Myelogenous Leukemia | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 344 | 1998-10-22 | 2019-08-12 |
| SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) PEG-Intron, INTRON A - Melanoma | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 126 | 1998-08-05 | 2019-07-24 |
Melanoma (3) · Carcinoma, Renal Cell (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Follicular (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Roswell Park Cancer Institute (4) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · Duke University (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Medicine and Dentistry of New Jersey (1)
United States (10) · Canada (1)
Igor Puzanov (2) · Amer H Zureikat, MD (1) · Ana M. Aparicio, MD (1) · Daniel George (1) · Ellis Levine, MD (1) · John Sweetenham (1) · Lorna Rodriguez, MD, PhD (1) · Michael Morse, MD (1) · Morris D. Groves, MD, JD (1)
P01CA234212 (2), P30CA016056 (1), P30CA072720 (1), U01CA099118 (1)